查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988347

同种异体细胞疗法市场：2026-2032年全球市场预测（依产品类型、生产技术、适应症、细胞来源和最终用户划分）

Allogeneic Cell Therapy Market by Product Type, Manufacturing Technology, Indication, Cell Source, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，同种异体细胞疗法市场价值将达到 26.4 亿美元，到 2026 年将成长至 30.2 亿美元，到 2032 年将达到 67.9 亿美元，复合年增长率为 14.44%。

主要市场统计数据
基准年 2025 26.4亿美元
预计年份：2026年 30.2亿美元
预测年份 2032 67.9亿美元
复合年增长率 (%) 14.44%

对当前同种异体细胞疗法趋势的策略性展望，重点在于商业化准备、监管合规性和生产挑战。

本执行摘要首先明确阐述了同种异体细胞疗法的当前发展趋势，并将该技术置于再生医学和免疫疗法更广泛的发展脉络中。同种异体细胞疗法有望实现即时供应、产品品质稳定，并有望突破自体疗法在临床供应方面的局限性，从而改变研发者、生产商和支付方的决策标准。因此，相关人员正将投资重点从一次性个体生产转向可扩展的生产平台和标准化管理策略。

生物製程技术、免疫工程和经营模式的融合发展如何重塑同种异体细胞疗法的发展路径和投资重点。

在异体细胞治疗领域，技术进步、监管预期变化和经营模式演进共同推动变革。生产技术的进步，例如一次性生物反应器的成熟、精密的微载体系统和3D培养平台，提高了产量、改善了细胞质量，并实现了更可预测的规模化生产。这些技术变革降低了技术风险，加速了从实验室生产到大量生产的过渡，并最终吸引了更多投资进入后期临床专案。

预测新关税措施对美国细胞治疗生态系统的供应链韧性、资本规划和监管合规性的累积影响。

美国在2025年实施的累积关税可能透过多种机制对同种异体细胞疗法的整个价值链产生影响。首先，对进口试剂、一次性组件和专用设备征收关税将增加依赖全球供应商的製造商的接收成本，从而改变研发商和契约製造的成本结构预期。为因应此变化，各机构可能会加快在地化供应、认证国内供应商或垂直整合关键上游工程投入的步伐，以降低贸易政策变化所带来的风险。

以细分市场主导的洞察，将最终用户角色、製造平台选择、适应症优先顺序、细胞来源和产品模式与策略发展路径连结起来。

基于细分观点，我们可以清楚地了解整个异体细胞治疗价值链中科学、运作和商业性机会的集中位置。对终端使用者的分析表明，合约研究组织（CRO）是早期和后期研发阶段的重要合作伙伴，提供专业的临床实验物流和流程转移能力。另一方面，医院和专科诊所则作为关键的交付中心，需要与临床工作流程和低温运输物流进行整合。研究机构仍然是转化创新和生物标记发现的重要来源，为下游开发平臺提供支援。

区域趋势和战略挑战正在影响美洲、欧洲、中东和非洲以及亚太地区的临床策略、製造地和市场进入。

区域趋势为在美洲、欧洲、中东和非洲以及亚太地区营运的相关人员带来了不同的策略挑战。在美洲，临床活动高度集中，生产基础设施投入庞大，这不仅支持了药物的快速上市，也加剧了对熟练人才和专业设施的竞争。因此，在该地区营运的公司越来越重视扩充性的模组化生产系统和战略伙伴关係关係，以加速实用化向临床试验的过渡。

决定细胞疗法开发中竞争地位和业务永续营运的企业策略、伙伴关係和生产能力。

每家公司的策略都展现了它们在异体细胞治疗生态系统中应对竞争与合作的独特方式。主要企业正集中资源将差异化科学转化为临床优势，同时建构或巩固后期临床试验和商业化所需的生产能力。契约製造组织 (CMO) 和专业技术供应商发挥着至关重要的作用，它们提供可扩展的平台和监管方面的专业知识，使规模小规模的研发公司能够在无需巨额资本投入的情况下推进业务发展。

为高阶主管提供实用建议，以协调转化科学、生产规模化、供应链韧性和支付方合作，从而推动商业化成功。

产业领导者应采取一系列切实可行的步骤，使科学目标与营运可行性和商业性价值一致。首先，在专案设计的早期阶段优先考虑整合製程开发，同时优化细胞产品特性和可扩展的生产能力，从而避免后期开发阶段代价高昂的重新设计。儘早协调转化科学、程式工程和监管策略，可以缩短临床试验时间，并增强监理申报的效力。

采用混合研究途径，结合文献整合、专家访谈、技术检验和案例研究检验，以支持实务见解。

本分析采用混合方法，整合质性和量性讯息，旨在确保研究的严谨性和有效性。我们收集了最新的科学文献、同行评审的转化研究、监管指导文件、临床试验註册数据以及公开的企业资讯披露，以确定技术、临床开发和政策方面的基准趋势。这些资讯来源提供了必要的技术和监管背景，有助于解读基因编辑、细胞工程和製造技术的最新进展。

总结技术成熟度、业务永续营运和监管一致性如何决定哪些同种异体细胞疗法计画能够取得持续的临床和商业性影响。

总之，异体细胞疗法领域正处于一个转折点，技术成熟度、供应链策略和监管调整在此交汇，决定哪些计画能够取得持续的临床和商业性成功。虽然现成产品有可能扩大患者群体并实现更有效率的给药模式，但要真正发挥这种潜力，需要在科学设计、生产规模化和与支付方的合作方面进行精心协调。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 同种异体细胞疗法市场：依产品类型划分

  • CAR-T疗法
    • 基因改造
    • 没有基因改造
  • 树突细胞疗法
    • 未成熟树突状细胞
    • 成熟树突状细胞
  • NK细胞疗法
    • 基因改造
    • 未修改
  • 干细胞疗法
    • 造血系统
    • 间质

第九章 依製造技术分類的同种异体细胞疗法市场

  • 二维培养系统
    • 分层烧瓶
    • 滚珠瓶
  • 3D球状体培养
    • 使用鹰架
    • 没有鹰架
  • 生物反应器系统
    • 多用途
    • 一次使用
  • 基于微载体的系统
    • 固定台
    • 搅拌罐

第十章：同种异体细胞疗法市场：依适应症划分

  • 自体免疫疾病
    • 狼疮
    • 多发性硬化症
    • 类风湿性关节炎
  • 心血管疾病
    • 心肌梗塞
    • 周边动脉疾病
    • 中风
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 神经系统疾病
    • 阿兹海默症
    • 帕金森氏症
    • 脊髓损伤
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌

第十一章 依细胞来源分類的同种异体细胞疗法市场

  • 脂肪组织
  • 骨髓
  • 週边血
  • 脐带

第十二章 同种异体细胞疗法市场：依最终用户划分

  • 合约研究机构
  • 医院
  • 研究机构
  • 专科诊所

第十三章 同种异体细胞疗法市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 同种异体细胞疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 同种异体细胞疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国异体细胞疗法市场

第十七章：中国异体细胞治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals
Product Code: MRR-CA100284D019

The Allogeneic Cell Therapy Market was valued at USD 2.64 billion in 2025 and is projected to grow to USD 3.02 billion in 2026, with a CAGR of 14.44%, reaching USD 6.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.64 billion
Estimated Year [2026] USD 3.02 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 14.44%

A strategic orientation to the current allogeneic cell therapy landscape that highlights commercialization readiness, regulatory alignment, and manufacturing imperatives

This executive summary opens with a clear orientation to the current allogeneic cell therapy landscape, situating the technology within the broader evolution of regenerative medicine and immunotherapy. Allogeneic approaches promise off-the-shelf availability, consistent product quality, and the potential to decouple clinical supply from autologous constraints, which changes the calculus for developers, manufacturers, and payers. As a result, stakeholders are shifting investments from one-off individualized production toward scalable manufacturing platforms and standardized control strategies.

In parallel, clinical development is moving beyond proof-of-concept into more complex trials that evaluate durability, safety across diverse patient populations, and real-world deliverability. Regulatory pathways are adapting, with agencies emphasizing robust comparability, potency assays, and supply chain traceability. Consequently, development teams must integrate translational science, process engineering, and regulatory strategy earlier in product design. This introduction frames the subsequent sections by highlighting the intersection of technology maturation, commercialization readiness, and the operational imperatives that determine which programs will progress from clinical promise to clinical practice.

How convergent advances in bioprocess technologies, immune engineering, and commercial models are reshaping development pathways and investment priorities in allogeneic cell therapy

The allogeneic cell therapy arena is experiencing transformative shifts driven by converging technological advances, evolving regulatory expectations, and shifting commercial models. Advances in manufacturing technology, including the maturation of single-use bioreactors, refined microcarrier systems, and three-dimensional culture platforms, are enabling higher yields, improved cell quality, and more predictable scalability. These technological changes reduce technical risk and accelerate the transition from bench to batch, which in turn attracts broader investment into late-stage clinical programs.

Concurrently, gene editing and immune engineering techniques are expanding the therapeutic scope by enabling universal donor constructs, alleviating host-versus-graft reactions, and improving persistence in vivo. These biological innovations are reshaping clinical development strategies and creating new regulatory questions around genetic modification, long-term follow-up, and assay standardization. As these techniques become more standardized, they drive a secondary wave of process innovation focused on integrating genetic manipulation into closed, GMP-compliant production flows.

Commercial models are also shifting. Payers and providers increasingly evaluate total cost of care and prefer therapies that can be delivered reliably at scale. This expectation places a premium on reproducible manufacturing, supply chain resilience, and demonstrable long-term benefits. As a result, partnerships between developers, contract research organizations, and manufacturing technology suppliers are becoming more strategic and long-term in nature, emphasizing shared platform investments and co-development of analytic methods. Taken together, these shifts compress timelines from discovery to commercialization for programs that align scientific innovation with scalable manufacturing and comprehensive regulatory strategies.

Projected cumulative impacts of new tariff measures on supply chain resilience, capital planning, and regulatory compliance within the United States cell therapy ecosystem

The introduction of cumulative United States tariffs in 2025 has the potential to reverberate across the allogeneic cell therapy value chain through several distinct mechanisms. First, tariffs on imported reagents, single-use components, and specialized equipment will increase landed costs for manufacturers that rely on global suppliers, thereby altering cost-structure assumptions for both developers and contract manufacturers. In response, organizations may accelerate efforts to localize supply, qualify domestic suppliers, or vertically integrate critical upstream inputs to reduce exposure to trade policy volatility.

Second, increased import costs can lengthen lead times and complicate inventory strategies for clinical and commercial supply. Developers running multi-site clinical programs may find logistics and cold-chain requirements more complex, prompting tighter coordination between clinical sites and manufacturing centers. This could encourage regionalization of supply chains, where production closer to patient populations reduces cross-border movement and mitigates tariff exposure, but it may also create disparities in access if regional manufacturing capacity is uneven.

Third, tariffs can influence capital allocation decisions. When imported capital equipment becomes more expensive, companies may delay or downsize planned investments in advanced bioreactor systems or automation. Conversely, they may prioritize modular, lower-capex solutions or seek leasing and vendor finance models to preserve capital for clinical development. This shift can slow the adoption of higher-throughput platforms in the short term while stimulating innovation in cost-effective manufacturing solutions.

Fourth, trade barriers tend to catalyze strategic realignments among suppliers and service providers. International suppliers may establish local production or distribution arms to retain market access, while domestic manufacturers could expand capacity to meet rising demand. Strategic partnerships, co-manufacturing agreements, and licensing arrangements may proliferate as firms seek to hedge tariff risk and maintain supply continuity.

Lastly, tariffs have implications for regulatory and compliance efforts. The need to qualify alternative suppliers and adapt validated processes to different component specifications increases the regulatory burden and operational complexity. Manufacturers will need to document comparability studies and potentially update regulatory filings, which can extend timelines and divert resources from other development priorities. Overall, the cumulative effect of tariffs in 2025 encourages a reappraisal of supply chain architecture, capital planning, and regulatory contingency strategies across the sector.

Segment-driven insights that map end-user roles, manufacturing platform choices, indication priorities, cell sources, and product modalities to strategic development pathways

A segmentation-driven view clarifies where scientific, operational, and commercial opportunities cluster across the allogeneic cell therapy value chain. When examining end users, Contract Research Organizations act as essential partners for early and late-stage development, providing specialized trial logistics and process transfer capabilities, whereas hospitals and specialty clinics function as primary delivery points that require integration with clinical workflows and cold-chain logistics. Research institutes remain critical sources of translational innovation and biomarker discovery that feed downstream development pipelines.

Manufacturing technology choices shape both product attributes and cost dynamics. Two-dimensional culture systems, historically used for early development, remain relevant for specific workflows but must evolve to meet scale demands through layered flasks and roller bottle formats. Three-dimensional spheroid culture approaches, whether scaffold-based or scaffold-free, are gaining traction for applications where native-like microenvironments enhance potency. Bioreactor systems, transitioning between multi-use and single-use configurations, are central to achieving closed-system processing and reducing contamination risk. Microcarrier based systems, including fixed bed and stirred tank variants, provide flexible routes to increase cell density while preserving phenotype, yet each technology requires bespoke analytics and downstream processing adaptations.

Indication segmentation highlights how therapeutic focus influences product design and development strategy. Autoimmune disorders such as lupus, multiple sclerosis, and rheumatoid arthritis demand durable immunomodulation with favorable safety margins. Cardiovascular indications like myocardial infarction, peripheral artery disease, and stroke prioritize tissue repair and functional recovery, which often requires delivery strategies that ensure cell retention and engraftment. Infectious disease applications, divided between bacterial and viral infections, necessitate rapid deployability and robust safety profiling. Neurological targets including Alzheimer's, Parkinson's, and spinal cord injury confront delivery barriers and the need for long-term durability, while oncology applications for hematological malignancies and solid tumors impose stringent efficacy thresholds and complex combination strategies.

Cell source and product type further influence manufacturing and regulatory strategy. Sources such as adipose tissue, bone marrow, peripheral blood, and umbilical cord each present unique harvest logistics, cell yields, and donor variability that affect upstream processing and donor screening. Product types including CAR-T constructs, dendritic cell therapies, NK cell therapies, and diverse stem cell approaches demand tailored genetic engineering, activation, and expansion workflows. Subcategories-such as gene edited versus non-gene edited CAR-T, immature versus mature dendritic cell preparations, engineered versus unmodified NK cells, and hematopoietic versus mesenchymal stem cell therapies-introduce additional analytical and comparability requirements. In practice, the most promising programs align indication biology with an optimized cell source and manufacturing platform that together address clinical need while minimizing process complexity.

Regional dynamics and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape clinical strategy, manufacturing footprint, and market access

Regional dynamics create differentiated imperatives for stakeholders operating across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated clinical activity and substantial investment into manufacturing infrastructure, which supports rapid translation but also heightens competition for skilled talent and specialized facility capacity. Consequently, firms operating here often emphasize scalable, modular manufacturing systems and strategic partnerships to accelerate time to clinic.

Within Europe, Middle East & Africa, regulatory frameworks and market access policies vary across jurisdictions, shaping multi-country clinical strategies and commercial launch sequencing. Harmonization efforts and collaborative networks foster cross-border clinical programs, but developers must navigate diverse reimbursement models and national regulatory nuances. This region typically encourages strong center-of-excellence models that concentrate complex procedures at specialized institutions.

The Asia-Pacific region combines rapid clinical expansion with growing manufacturing capabilities and an appetite for public-private collaboration. Local investment in cell therapy research and domestic supplier ecosystems is increasing, creating opportunities to optimize cost structures and localize production. However, developers must account for heterogeneous regulatory maturity and varying standards for clinical trial design and post-market surveillance. Across all regions, cross-border collaboration and manufacturing footprint decisions will determine program resilience, patient access, and long-term sustainability.

How corporate strategies, partnerships, and manufacturing capabilities define competitive positioning and operational resilience in cell therapy development

Company strategies reveal distinct approaches to competing and collaborating within the allogeneic cell therapy ecosystem. Leading developers concentrate resources on translating differentiating science into clinical advantage while building or securing access to the manufacturing capacity required for late-stage trials and commercialization. Contract manufacturing organizations and specialized technology suppliers play a pivotal role by offering scalable platforms and regulatory expertise that enable smaller developers to advance without large capital expenditures.

Strategic partnerships, licensing agreements, and selective vertical integration are common responses to the challenge of delivering consistent product quality at scale. Firms that invest early in robust analytical development and potency assays reduce downstream comparability risk and accelerate regulatory interactions. Moreover, companies that diversify supplier bases and qualify alternative sources for critical raw materials demonstrate greater resilience to supply disruptions.

Competitive positioning also depends on how firms manage intellectual property, gene-editing platforms, and cell engineering know-how. Organizations that cultivate strong manufacturing knowledge transfer processes and invest in workforce training produce more reliable technology transfers and faster scale-up. Finally, corporate strategies increasingly reflect commercial considerations such as payer engagement, evidence generation for real-world outcomes, and the development of service-oriented offerings that bundle therapy supply with training and site support to facilitate adoption.

Practical recommendations for executives to align translational science, manufacturing scale-up, supply chain resilience, and payer engagement to drive commercialization success

Industry leaders should pursue a set of actionable measures that align scientific ambition with operational feasibility and commercial viability. First, prioritize integrated process development that co-optimizes cell product attributes and scalable manufacturing early in program design to avoid costly redesigns later in development. Early alignment between translational science, process engineering, and regulatory strategy reduces time to clinic and strengthens regulatory submissions.

Second, diversify supplier relationships for critical consumables and components while qualifying domestic alternatives where feasible to mitigate tariff and geopolitical risks. Securing multi-sourced supply chains and building inventory strategies tied to clinical milestones will protect trial continuity and commercial launch readiness. Third, invest in robust analytical platforms and potency assays that demonstrate mechanism of action and clinical relevance. Strong analytical evidence supports both regulatory interactions and payer discussions by connecting manufacturing control to clinical outcomes.

Fourth, consider flexible manufacturing models that combine internal capacity with strategic use of contract manufacturing organizations. This hybrid approach balances control over critical processes with the ability to scale rapidly when clinical or commercial demand materializes. Fifth, engage payers and health systems early to define value frameworks, real-world evidence requirements, and delivery pathways. Proactive engagement reduces reimbursement uncertainty and informs clinical trial endpoints that matter to stakeholders.

Finally, cultivate talent through targeted hiring and training programs focused on cell therapy manufacturing, quality systems, and regulatory affairs. Workforce readiness remains a bottleneck; investing in capability development will accelerate commercialization and improve operational quality. Together, these actions create a resilient, scalable pathway from laboratory innovation to sustainable patient access.

A mixed-method research approach combining literature synthesis, expert interviews, technology validation, and case study triangulation to underpin actionable insights

This analysis synthesizes qualitative and quantitative inputs using a mixed-method approach designed to ensure rigor and relevance. We compiled contemporary scientific literature, peer-reviewed translational studies, regulatory guidance documents, clinical trial registries, and publicly available corporate disclosures to establish baseline trends in technology, clinical development, and policy. These sources provided the technical and regulatory context necessary to interpret recent advances in gene editing, cell engineering, and manufacturing modalities.

We complemented documentary research with structured interviews of domain experts spanning developers, contract manufacturers, clinical investigators, and regulatory affairs professionals to capture operational realities and strategic intent. Interview findings were triangulated with process descriptions and technology specifications from equipment and reagent suppliers to validate assumptions about scalability, comparability, and supply chain dependencies. Where applicable, anonymized case studies of recent process transfers and scale-up efforts informed practical guidance on risk mitigation and resource allocation.

Analytic rigor was maintained through cross-validation of claims, assessment of methodological biases, and explicit acknowledgement of data limitations. The study emphasizes reproducible methods and transparent assumptions, and it identifies areas where further primary data collection would strengthen decision-making. This methodology balances depth of insight with the need for actionable recommendations targeted to executives and technical leaders.

Concluding synthesis on how technological readiness, operational resilience, and regulatory alignment will determine which allogeneic programs achieve sustained clinical and commercial impact

In conclusion, the allogeneic cell therapy field stands at an inflection point where technological maturation, supply chain strategy, and regulatory adaptation converge to determine which programs will achieve durable clinical and commercial success. Off-the-shelf products can unlock broader patient access and streamlined delivery models, but realizing that potential requires deliberate alignment across scientific design, manufacturing scalability, and payer engagement.

Operational resilience-evidenced by diversified sourcing, robust analytics, and flexible manufacturing-will distinguish leaders from laggards. Meanwhile, regulatory clarity around gene editing, potency assays, and post-market surveillance will shape development priorities and evidence generation strategies. Finally, regional footprint decisions and responses to trade policy shifts will materially affect cost structures and access pathways. The organizations that integrate these dimensions into coherent development programs will be best positioned to translate clinical promise into sustained patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Cell Therapy Market, by Product Type

  • 8.1. CAR-T Therapy
    • 8.1.1. Gene Edited
    • 8.1.2. Non Gene Edited
  • 8.2. Dendritic Cell Therapy
    • 8.2.1. Immature Dendritic
    • 8.2.2. Mature Dendritic
  • 8.3. NK Cell Therapy
    • 8.3.1. Engineered
    • 8.3.2. Unmodified
  • 8.4. Stem Cell Therapy
    • 8.4.1. Hematopoietic
    • 8.4.2. Mesenchymal

9. Allogeneic Cell Therapy Market, by Manufacturing Technology

  • 9.1. 2D Culture Systems
    • 9.1.1. Layered Flasks
    • 9.1.2. Roller Bottles
  • 9.2. 3D Spheroid Culture
    • 9.2.1. Scaffold Based
    • 9.2.2. Scaffold Free
  • 9.3. Bioreactor Systems
    • 9.3.1. Multi Use
    • 9.3.2. Single Use
  • 9.4. Microcarrier Based Systems
    • 9.4.1. Fixed Bed
    • 9.4.2. Stirred Tank

10. Allogeneic Cell Therapy Market, by Indication

  • 10.1. Autoimmune Disorders
    • 10.1.1. Lupus
    • 10.1.2. Multiple Sclerosis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Cardiovascular Diseases
    • 10.2.1. Myocardial Infarction
    • 10.2.2. Peripheral Artery Disease
    • 10.2.3. Stroke
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Viral Infections
  • 10.4. Neurological Disorders
    • 10.4.1. Alzheimers
    • 10.4.2. Parkinsons
    • 10.4.3. Spinal Cord Injury
  • 10.5. Oncology
    • 10.5.1. Hematological Malignancies
    • 10.5.2. Solid Tumors

11. Allogeneic Cell Therapy Market, by Cell Source

  • 11.1. Adipose Tissue
  • 11.2. Bone Marrow
  • 11.3. Peripheral Blood
  • 11.4. Umbilical Cord

12. Allogeneic Cell Therapy Market, by End User

  • 12.1. Contract Research Organization
  • 12.2. Hospital
  • 12.3. Research Institute
  • 12.4. Specialty Clinic

13. Allogeneic Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Allogeneic Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Allogeneic Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Allogeneic Cell Therapy Market

17. China Allogeneic Cell Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abeona Therapeutics Inc.
  • 18.6. AlloSource
  • 18.7. Anterogen.Co., Ltd.
  • 18.8. Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • 18.9. Athersys Inc.
  • 18.10. Biorestorative Therapies Inc.
  • 18.11. Biosolution Co., Ltd.
  • 18.12. Bloodworks Northwest
  • 18.13. Brainstorm Cell Limited
  • 18.14. Caribou Biosciences
  • 18.15. Fate Therapeutics
  • 18.16. Gamida Cell
  • 18.17. Hope Biosciences
  • 18.18. JCR Pharmaceuticals Co., Ltd.
  • 18.19. Mallinckrodt Pharmaceuticals
  • 18.20. MEDIPOST Co., Ltd.
  • 18.21. Mesoblast Ltd.
  • 18.22. NuVasive Inc. by Globus Medical
  • 18.23. RTI Surgical
  • 18.24. Smith+Nephew PLC
  • 18.25. Stempeutics Research Pvt. Ltd.
  • 18.26. Sumitomo Pharma Co., Ltd.
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Tego Science Inc.
  • 18.29. ViaCyte Inc. by Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ENGINEERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UNMODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ALLOGENEIC CELL THER